Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Tvardi Therapeutics, Inc. (TVRD) is a Biotechnology company based in US with a market capitalization of $26.8M. Free cash flow was negative at -$23.5M. This page tracks TVRD's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 17 employees · IPO Apr 16, 2025
Valuation
Valuation & price
$4.00as of May 17, 2026· -90.7% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
1.28
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$26.8M
Market cap
—
Revenue growth (YoY)
88.6%
Gross margin
-$23.5M
Free cash flow (USD)
-$30.6M
Net debt
Net cash position
387.8%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2020 → 2025
Free cash flow by year
2020 → 2025
Gross margin by year
2021 → 2024
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 8, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Tvardi Therapeutics, Inc.'s market cap?
Tvardi Therapeutics, Inc. (TVRD) has a market capitalization of $26.8M.
What is TVRD's P/E ratio?
A meaningful P/E ratio is not available for TVRD — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is TVRD's price-to-book (P/B) ratio?
TVRD trades at 1.28 times book value per share.
Are insiders buying TVRD stock?
SEC Form 4 filings show no open-market insider buys at Tvardi Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.